These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6331304)

  • 21. Uptake of [125I]iododeoxycytidine by cells infected with herpes simplex virus: a rapid screening test for resistance to acyclovir.
    Van Dyke RB; Connor JD
    J Infect Dis; 1985 Dec; 152(6):1206-11. PubMed ID: 2999258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.
    Hill EL; Hunter GA; Ellis MN
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2322-8. PubMed ID: 1666496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice.
    Lobe DC; Spector T; Ellis MN
    Antiviral Res; 1991 Feb; 15(2):87-100. PubMed ID: 1650166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan.
    Hasegawa T; Kawana T; Okuda T; Horii M; Tsukada T; Shiraki K
    J Med Virol; 2001 Jan; 63(1):57-63. PubMed ID: 11130888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.
    Sibrack CD; McLaren C; Barry DW
    Am J Med; 1982 Jul; 73(1A):372-5. PubMed ID: 6285725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuronal control of herpes simplex virus latency.
    Tenser RB; Edris WA; Hay KA
    Virology; 1993 Aug; 195(2):337-47. PubMed ID: 8393231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.
    Ellis MN; Waters R; Hill EL; Lobe DC; Selleseth DW; Barry DW
    Antimicrob Agents Chemother; 1989 Mar; 33(3):304-10. PubMed ID: 2543278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Herpes simplex virus latent infection: reactivation and elimination of latency after neurectomy.
    Tenser RB; Edris WA; Hay KA
    Virology; 1988 Nov; 167(1):302-5. PubMed ID: 2847420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary characterization of a mutant of herpes simplex virus type 1 selected for acycloguanosine resistance in vitro.
    Palú G; Summers WP; Valisena S; Tognon M
    J Med Virol; 1988 Mar; 24(3):251-62. PubMed ID: 2835423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus.
    Saijo M; Suzutani T; Itoh K; Hirano Y; Murono K; Nagamine M; Mizuta K; Niikura M; Morikawa S
    J Med Virol; 1999 Aug; 58(4):387-93. PubMed ID: 10421406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals.
    van Velzen M; van Loenen FB; Meesters RJ; de Graaf M; Remeijer L; Luider TM; Osterhaus AD; Verjans GM
    J Infect Dis; 2012 May; 205(10):1539-43. PubMed ID: 22457282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity.
    Tanaka S; Toh Y; Mori R
    Arch Virol; 1993; 131(1-2):61-73. PubMed ID: 8392322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations.
    Bernstein DI; Ireland J; Bourne N
    Antiviral Res; 2000 Sep; 47(3):159-69. PubMed ID: 10974368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child.
    Sibrack CD; Gutman LT; Wilfert CM; McLaren C; St Clair MH; Keller PM; Barry DW
    J Infect Dis; 1982 Nov; 146(5):673-82. PubMed ID: 6290575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.
    Ellis MN; Lobe DC; Spector T
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1691-6. PubMed ID: 2556074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virus-drug resistance: thymidine kinase-deficient (TK-) mutants of herpes simplex virus. Therapeutic approaches.
    de Clercq E
    Ann Ist Super Sanita; 1987; 23(4):841-7. PubMed ID: 2837935
    [No Abstract]   [Full Text] [Related]  

  • 37. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization.
    Stránská R; Schuurman R; Nienhuis E; Goedegebuure IW; Polman M; Weel JF; Wertheim-Van Dillen PM; Berkhout RJ; van Loon AM
    J Clin Virol; 2005 Jan; 32(1):7-18. PubMed ID: 15572000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity monitoring of herpes simplex virus isolates from patients receiving acyclovir.
    Collins P; Oliver NM
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():103-12. PubMed ID: 3025149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Resistance of herpes simplex viruses to antiviral drugs].
    Scieux C; Bianchi A
    Pathol Biol (Paris); 1993 Feb; 41(2):172-7. PubMed ID: 8392160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency.
    Schinazi RF; del Bene V; Scott RT; Dudley-Thorpe JB
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():127-34. PubMed ID: 3025153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.